ImmUniverse

Description
Immuniverse research projects at LCSB aim at to better control and treatment of immune-mediated diseases by exploring the universe of microenvironment-imposed tissue signatures and their correlates in liquid biopsies. The precise aims of the ImmUniverse project are given below: Objective 1. Comprehensive molecular characterization of intestinal/dermal microenvironment and immune cell profiles that provides a data foundation for advanced bioinformatics, statistical and model-based analysis. Objective 2. Confirmation of the identified signatures in tissue and blood samples from a large retrospective and longitudinal cohort and in a non-interventional prospective clinical study. Objective 3. Evaluation of evolving technologies such as dermal open-flow microperfusion and ultrasound-enabled gut liquid biopsy as non-invasive approaches for the identification of new ―microinvasive‖ biomarkers suitable to reflect clinically relevant tissue-based signatures of disease progression and/or response to treatment. Objective 4. Integrated large-scale data storage and computing platform to collect, curate, harmonize and standardize the newly and previously generated data. Objective 5. Having included excellent SME partners and incorporating large industry partners, we will improve the competitiveness of European industry and support the development of biomarkers, which will benefit patients.
Accession number
ELU-1-0A6EF9-1
Project acronym
ImmUniverse
Project website
Start date
2020-01-01
End date
2024-12-31
Funding
IMI2 - Call 15 (Grant number 853995)
Types
Accession number Title Create date Study hosted at UL
ELU-2-5418BA-1 Lilly Ulcerative Colitis data 2024-05-20 LUCENT-1 (NCT 03518086) Yes
ELU-2-C0D6E1-1 ph2a/b study in ulcerative colitis 2022-09-05 204869 Phase 2a/b in Ulcerative Colitis Yes
ELU-2-362C0E-1 Pfizer UC 2023-09-05 Pfizer (NCT02958865) Yes
ELU-2-181F72-1 AMC dataset - AMCUC study Yes
ELU-2-B13148-1 203167 Phase 2a in Psoriasis 2025-02-26 203167 Phase 2a in Psoriasis Yes
ELU-2-6F51D5-1 Pfizer Olink Serum in Ulcerative Colitis deprecated 2023-09-08 Pfizer (NCT02958865) Yes
ELU-2-DEE817-1 Pfizer Olink Tissue in Ulcerative Colitis deprecated 2023-09-08 Pfizer (NCT02958865) Yes
ELU-2-C28DB2-1 Pfizer Vibrato Brepo Blood in Ulcerative Colitis deprecated 2023-09-08 Pfizer (NCT02958865) Yes
ELU-2-EA17D1-1 Pfizer Vibrato Brepo Tissue in Ulcerative Colitis deprecated 2023-09-08 Pfizer (NCT02958865) Yes
ELU-2-D7FB95-1 Pfizer Vibrato Ritle Tissue in Ulcerative Colitis deprecated 2023-09-08 Pfizer (NCT02958865) Yes
ELU-2-CE767B-1 Pfizer Vibrato Ritle Blood in Ulcerative Colitis deprecated 2023-09-08 Pfizer (NCT02958865) Yes
19ac4754-5f50-11ed-a1b3-acde48001122 TREATgermany - Transcriptomics deprecated 2022-11-08 TREATgermany Yes
2b73a220-5f50-11ed-a1b3-acde48001122 TREATgermany - Microbiome deprecated 2022-11-08 TREATgermany Yes
e032b278-91c8-11ed-97aa-acde48001122 P2N ADPSOKO - Methylome deprecated 2023-01-10 P2N ADPSOKO No
e032b75a-91c8-11ed-97aa-acde48001122 P2N ADPSOKO - Transcriptome deprecated 2023-01-10 P2N ADPSOKO No
Hide deprecated records
Title Primary purpose Study type Organism
LUCENT-1 (NCT 03518086) Lilly Lucent imaging in Ulcerative Colitis
C71104
Homo sapiens
204869 Phase 2a/b in Ulcerative Colitis 204869 Phase 2a/b in Ulcerative Colitis
C71104
Homo sapiens
Pfizer (NCT02958865) Pfizer
C71104
NCT02958865
Homo sapiens
AMCUC study AMCUC study
C71104
Homo sapiens
203167 Phase 2a in Psoriasis 203167 Phase 2a in Psoriasis
C71104
Homo sapiens
TREATgermany TREATgermany
biosamples transcriptomics microbiome
Homo sapiens
P2N ADPSOKO P2N ADPSOKO
biosamples transcriptomics methylome
Homo sapiens